|
|
|
|
Patients With Long-Term Conditions Need Greater Support To Return To Work, England
A new study has identified a significant shortfall in patients with life-long but treatable conditions re-entering employment.The research is being presented at the annual Society for Endocrinology BES meeting in Manchester. Led by Prof John Wass of the...
|
|
|
Patients with chronic conditions need support to re-enter employment
A new study has identified a significant shortfall in patients with life-long but treatable conditions re-entering employment.The research is being presented at the annual Society for Endocrinology BES meeting in Manchester. Led by Prof John Wass of the...
|
|
|
Significant Incidence of Adrenal Masses in Patients With Gastroenteropancreatic Neuroendocrine Tumours: Presen
-- Incidental adrenal lesions are commonly seen in patients who have gastroenteropancreatic neuroendocrine tumours (GEP-NETs), according to a study presented here at the 7th Annual European Neuroendocrine Tumor Society (ENETS) Conference.George Kanakis, MD,...
|
|
|
Removing Tumors
Each year, up to 15-million Americans are diagnosed with Cushing's syndrome.It occurs when the body is exposed to high levels of the hormone cortisol, often caused by a benign tumor deep inside the brain. Removing Tumors.
|
|
|
Ritonavir, Inhaled Fluticasone Interact to Create Cushing's Syndrome Symptoms: Presented at AAAAI
-- A potent inhibitor of cytochrome P450 that is often used in patients with HIV may interact with inhaled fluticasone to create a condition of adrenal suppression and symptoms that can result in a diagnosis of Cushing's syndrome that may not be entirely...
|
|
|
Colon Cancer Alliance Undy 5000 5K Run/Walk
Liberty Station (Ingram Plaza - Cushing Rd.- Dewey Rd. - North Promenade Path Loop - Plaza Luce Court - South Promenade Path Loop - Roosevelt Rd. - Cushing Rd. Colon Cancer Alliance Undy 5000 5K Run/Walk.
|
|
|
Medical News: Corcept Therapeutics Initiates A Phase 1 Study Of Its Lead Selective Cortisol Receptor (GR-II) Antagonist -- CORT 108297
News Useful Links tweetmeme_source = 'mnt_psychology'; tweetmeme_service = 'bit.ly'; Main Category: Also Included In:/ Drug Trials; Mental Health Article Date: 24 Feb 2010 - 19:00 PST printer friendly Current Article Ratings: Patient / Public: Health...
|
|
|
Corcept Therapeutics Initiates A Phase 1 Study Of Its Lead Selective Cortisol Receptor (GR-II) Antagonist -- C
Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery and development of drugs for the treatment of severe metabolic and psychiatric disorders, has begun dosing in the Phase 1 study of its next-generation selective...
|
|
|
Predictive Value of Symptoms for Early Detection of Ovarian Cancer
Journal of the National Cancer Institute Advance Access originally published online on January 28, 2010 2010 102(4):222-229; doi:10.1093/jnci/djp500 This Article Full Text All Versions of this Article: 102/4/222 most recent djp500v1 Services Request Permissions...
|
|
|
Corcept Therapeutics Initiates a Phase 1 Study of Its Lead Selective Cortisol Receptor (GR-II) Antagonist -- CORT 108297
Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery and development of drugs for the treatment of severe metabolic and psychiatric disorders, has begun dosing in the Phase 1 study of its next-generation selective...
|
|
|
Corcept Therapeutics Initiates a Phase 1 Study of Its Lead Selective Cortisol Receptor (GR-II) Antagonist CORT
MENLO PARK, CA (MARKET WIRE) 02/23/10 Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery and development of drugs for the treatment of severe metabolic and psychiatric disorders, has begun dosing in the Phase 1...
|
|
|
Corcept Therapeutics Initiates a Phase 1 Study of Its Lead Selective Cortisol Receptor (GR-II) Antagonist -- CORT 108297
MENLO PARK, CA (MARKET WIRE) 02/23/10 Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery and development of drugs for the treatment of severe metabolic and psychiatric disorders, has begun dosing in the Phase 1...
|
|
|
Corcept Therapeutics Initiates a Phase 1 Study of Its Lead Selective Cortisol Receptor (GR-II) Antagonist -- CORT 108297
Companies mentioned in this article: Corcept Therapeutics MENLO PARK, CA -- (Marketwire) -- 02/23/10 -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery and development of drugs for the treatment of severe...
|
|
|
Medical Minute 2-22: Removing Tumors Through the Nose
Each year, 10 to 15-million Americans are diagnosed with Cushing's Syndrome which occurs when the body is exposed to high levels of the hormone cortisol, often caused by a benign tumor deep inside the brain.Now, doctors say a new kind of tool can make...
|
|
|
North Shore-LIJ Recruits Brain Cancer Specialist
The North Shore-LIJ Health Systems Harvey Cushing Institutes of Neuroscience today announced the appointment of neuro-oncologist Tulika Ranjan, MD.Trained at Memorial Sloan-Kettering (MSK) Cancer Center in Manhattan, Dr. Ranjan will collaborate with...
|
|
|
Cushing's Disease: Surgery Through the Nose
_ Cushing's Disease: Surgery Through the Nose.
|
|
|
Removing Tumors Through The Nose
removing these tumors an easier process on the patient.A year ago, Kelley felt like her body was out of control. 'I gained 120 pounds, went from being an extremely athletic person to not being able to do much at all without getting really sick,' Kelley...
|
|
|
Common meds may lower accuracy of test for Cushing's syndrome
NEW YORK (Reuters Health) - Many common medications - including some antidepressants and antihypertensives - can interfere with a test that distinguishes Cushing's syndrome from pseudo-Cushing's syndrome, investigators at Massachusetts General...
|
